Inventor · disambiguated record
Victor Kotelianski
Also filed as: KOTELIANSKI VICTOR · KOTELIANSKI VICTOR E
24 granted patents·20 pending applications·323 citations·filing 2000–2024
96Inventor score
Files withALNYLAM PHARMACEUTICALS INC11BIOGEN IDEC INC10DYNE THERAPEUTICS INC5BIOGEN MA INC2DE FOUGEROLLES ANTONIN R2
Top patents by PatentIndex Score
44 records- 0199US7605251B2Compositions and methods for inhibiting expression of the PCSK9 geneALNYLAM PHARMACEUTICALS INC·Filed 2007·Granted Oct 20, 2009·160 cites·20 claims
- 0292US8222222B2Compositions and methods for inhibiting expression of the PCSK9 geneTAN PAMELA·Filed 2009·Granted Jul 17, 2012·13 cites·27 claims
- 0392US2025171785A1Compositions and methods for inhibiting expression of the pcsk9 geneALNYLAM PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 0490US6652856B2Method for the treatment of fibrosisBIOGEN INC·Filed 2002·Granted Nov 25, 2003·34 cites·8 claims
- 0589US9260718B2Compositions and methods for inhibiting expression of the PCSK9 geneALNYLAM PHARMACEUTICALS INC·Filed 2014·Granted Feb 16, 2016·6 cites·27 claims
- 0689US8809292B2Compositions and methods for inhibiting expression of the PCSK9 geneTAN PAMELA·Filed 2012·Granted Aug 19, 2014·7 cites·38 claims
- 0789US6429303B1Nucleic acids encoding members of the human B lymphocyte activation antigen B7 family and methods of using the sameCURAGEN CORP·Filed 2000·Granted Aug 6, 2002·35 cites·9 claims
- 0887US9822365B2Compositions and methods for inhibiting expression of the PCSK9 geneALNYLAM PHARMACEUTICALS INC·Filed 2016·Granted Nov 21, 2017·3 cites·34 claims
- 0987US2024093199A1Compositions and methods for inhibiting expression of the pcsk9 geneALNYLAM PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 1086US8084031B2Method for the treatment of inflammatory disordersGOTWALS PHILIP·Filed 2008·Granted Dec 27, 2011·7 cites·15 claims
- 1186US6955810B2Method for the treatment of inflammatory disordersBIOGEN IDEC INC·Filed 2001·Granted Oct 18, 2005·20 cites·7 claims
- 1284US8557240B2Method for the treatment of inflammatory disordersGOTWALS PHILIP·Filed 2011·Granted Oct 15, 2013·6 cites·20 claims
- 1382US7405277B2Antibodies against monocyte chemotactic proteinsBIOGEN IDEC INC·Filed 2004·Granted Jul 29, 2008·10 cites·6 claims
- 1481US10501742B2Compositions and methods for inhibiting expression of the PCSK9 geneALNYLAM PHARMACEUTICALS INC·Filed 2017·Granted Dec 10, 2019·1 cites·19 claims
- 1580US7968680B2Polynucleotides encoding members of the human B lymphocyte activation antigen B7 family and polypeptides encoded therebyBIOGEN IDEC INC·Filed 2007·Granted Jun 28, 2011·4 cites·4 claims
- 1680US7888479B2Humanized antibodies against monocyte chemotactric proteinsBIOGEN IDEC INC·Filed 2003·Granted Feb 15, 2011·4 cites·46 claims
- 1779US9944671B2Compositions and methods directed to treating liver fibrosisHINKLE GREG·Filed 2011·Granted Apr 17, 2018·6 cites·8 claims
- 1878US2021403917A1Compositions and methods for inhibiting expression of the pcsk9 geneALNYLAM PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 1978US2020318119A1Compositions and Methods for Inhibiting Expression of the PCSK9 GeneALNYLAM PHARMACEUTICALS INC·Filed 2019·Application pending·0 cites
- 2077US9193973B2Compositions and methods for increasing erythropoietin (EPO) productionKAELIN JR WILLIAM G·Filed 2011·Granted Nov 24, 2015·2 cites·27 claims
- 2177US7972597B2Methods of reducing chemotaxis using antibodies against monocyte chemotactic proteinsBIOGEN IDEC INC·Filed 2009·Granted Jul 5, 2011·1 cites·1 claims
- 2277US7632501B2Antibodies against monocyte chemotactic proteinsBIOGEN IDEC INC·Filed 2008·Granted Dec 15, 2009·1 cites·29 claims
- 2375US8431125B2Methods of treating lupus nephritis using antibodies against monocyte chemotactic proteinsDE FOUGEROLLES ANTONIN R·Filed 2011·Granted Apr 30, 2013·2 cites·26 claims
- 2472US8519112B2Humanized antibodies against monocyte chemotactic proteinsDE FOUGEROLLES ANTONIN R·Filed 2011·Granted Aug 27, 2013·1 cites·9 claims
- 2566US10669303B2Compositions and methods directed to treating liver fibrosisALNYLAM PHARMACEUTICALS INC·Filed 2018·Granted Jun 2, 2020·0 cites·13 claims
- 2665US2024382513A1Muscle targeting complexes and uses thereof for modulation of genes associated with muscle healthDYNE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2765US2023203180A1Muscle targeting complexes and uses thereof for modulation of genes associated with muscle healthDYNE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2864US2025099603A9Muscle targeting complexes and uses thereof for treating friedreich's ataxiaDYNE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2964US2024294921A1Muscle targeting complexes and uses thereof for treating pompe diseaseDYNE THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3063US9096665B2Antibodies against monocyte chemotactic proteinsBIOGEN IDEC INC·Filed 2013·Granted Aug 4, 2015·0 cites·26 claims
- 3163US2021087218A1Compositions and methods directed to treating liver fibrosisALNYLAM PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 3260US2010010066A1Optimized Methods For Delivery Of DSRNA Targeting The PCSK9 GeneFITZGERALD KEVIN·Filed 2009·Application pending·0 cites
- 3360US2014079697A1Humanized antibodies against monocyte chemotactic proteinsBIOGEN IDEC INC·Filed 2013·Application pending·0 cites
- 3459US9902774B2Method for the treatment of inflammatory disordersBIOGEN MA INC·Filed 2013·Granted Feb 27, 2018·0 cites·44 claims
- 3556US10233452B2Compositions and methods for increasing erythropoietin (EPO) productionALNYLAM PHARMACEUTICALS INC·Filed 2015·Granted Mar 19, 2019·0 cites·25 claims
- 3656US2023111147A1Muscle targeting complexes and uses thereof for modulation of genes associated with muscle healthDYNE THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3756US2016185846A1Antibodies against monocyte chemotactic proteinsBIOGEN MA INC·Filed 2015·Application pending·0 cites
- 3853US2005281818A1Method for the treatment of fibrosisBIOGEN IDEC INC·Filed 2005·Application pending·0 cites
- 3951US2004037827A1Method for the treatment of fibrosisFiled 2003·Application pending·0 cites
- 4047US2012016009A1Optimized Methods For Delivery Of DSRNA Targeting The PCSK9 GeneFITZGERALD KEVIN·Filed 2011·Application pending·0 cites
- 4144US2003073823A1Novel transcription factor-like protein and nucleic acids encoding sameFiled 2001·Application pending·0 cites
- 4244US2007048321A1Method for the treatment of fibrosisGOTWALS PHILIP J·Filed 2006·Application pending·0 cites
- 4340US2007009518A1Methods for treating fibrotic conditionsBIOGEN IDEC INC·Filed 2006·Application pending·0 cites
- 4436US2002068287A1Methods of identifying integrin ligands using differential gene expressionFiled 2001·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →